What Transcenta does

Transcenta Holding Limited (HKEX: 06628) is a global clinical-stage biopharmaceutical company that integrates antibody-based biotherapeutics discovery, research and development, and GMP manufacturing under a single platform. Founded as MabSpace Biosciences in Suzhou in 2012 and reorganized via the 2019 merger with Hangzhou YI ANJES Biologics, the company operates two proprietary technology platforms: the Immune Tolerance Breaking Technology (IMTB) platform for generating therapeutic antibody candidates against difficult and conserved targets, and the Highly Intensified Continuous Bioprocessing (HiCB) platform that combines intensified continuous perfusion upstream processing with hybrid continuous downstream purification. HiCB delivers 10-15x productivity gains and at least 50% cost-of-goods reduction versus conventional fed-batch processes, and is operated through Transcenta's modular T-BLOC GMP facility in Hangzhou, which can produce up to 1,500 kg of protein annually with a 100% batch success rate across more than 50 GMP runs.

The company's clinical pipeline is led by Osemitamab (TST001), a high-affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced ADCC activity that is the second globally-developed CLDN18.2-targeting antibody and is currently in a global Phase III trial (TranStar301) for first-line G/GEJ cancer in combination with nivolumab. Additional pipeline assets include Blosozumab (TST002, licensed from Eli Lilly for Greater China) in Phase II for osteoporosis, TST003 (anti-Gremlin-1) in Phase I for solid tumors, TST004 (anti-MASP-2) for IgA nephropathy co-developed with Alebund, and earlier-stage ADCs and bispecifics. Osemitamab has received FDA Orphan Drug Designation for both G/GEJ cancer and pancreatic cancer.

Transcenta generates revenue across three streams: (1) CDMO services leveraging the T-BLOC facility and HiCB platform for external biotech and pharma clients; (2) non-exclusive out-licensing of the HiCB platform, with EirGenix (Taiwan) as the first licensee generating upfront, milestone, and future royalty payments; and (3) future commercialization of proprietary drug candidates, none of which have yet reached market. The company serves global pharmaceutical and biotechnology companies through direct B2B sales, technology licensing, and strategic co-development partnerships with major pharma (Bristol-Myers Squibb, Eli Lilly, Merck KGaA), and operates clinical development centers in China (Beijing, Shanghai, Guangzhou), the US (Princeton, NJ; partnering offices in Boston and Los Angeles), and Europe. Pricing for both CDMO services and licensing is negotiated on a project-by-project basis and is not publicly disclosed.

Name

Transcenta

Legal name

Transcenta Holding Limited

Website

https://transcenta.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Transcenta is a global clinical-stage biopharmaceutical company (HKEX: 06628) that integrates antibody-based biotherapeutics discovery, development, and GMP manufacturing, with a lead CLDN18.2 antibody in Phase III and a continuous bioprocessing platform licensed to CDMO partners.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Biologics contract manufacturing
• Antibody therapeutics development
• Continuous bioprocessing platform
• CDMO clinical supply services
• Oncology biopharmaceuticals

Headquarters

HQ city

Huangpu

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CDMO (Contract Development and Manufacturing Organization) Services: Transcenta leverages its T-BLOC modular GMP facility and HiCB continuous bioprocessing platform to provide contract manufacturing and development services to external biotech and pharma clients, generating revenue through service fees. The company has operated its CDMO business for over 5 years with 100% batch success rate, and the business continues to grow steadily.
2. Technology Licensing (HiCB Platform): Non-exclusive out-licensing of the HiCB (Highly Intensified Continuous Bioprocessing) platform to global CDMO and pharmaceutical partners. Revenue includes upfront payments, milestone payments, and ongoing royalties tied to commercial use of licensed technologies. The EirGenix agreement represents the first such licensing deal, with Transcenta receiving substantial upfront, milestone, and future royalty payments.
3. Drug Development and Commercialization: Development and eventual commercialization of proprietary antibody-based therapeutics (e.g., Osemitamab/TST001 in Phase III for G/GEJ cancer, TST002 in Phase II for osteoporosis, TST003 in Phase I for solid tumors). Revenue will derive from product sales upon regulatory approval, with global rights retained for core assets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Transcenta is a global clinical-stage biopharmaceutical company that develops antibody-based therapeutics (lead asset Osemitamab/TST001 in Phase III for CLDN18.2-positive gastric/GEJ and pancreatic cancer) and provides CDMO services plus HiCB continuous bioprocessing platform licensing to external pharma and biotech clients. It runs an integrated end-to-end capability from antibody discovery (IMTB) and translational research through process development, GMP manufacturing (T-BLOC facility), and global clinical development across China, the US, and Europe.

Product overview

Transcenta is a global clinical-stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development, and manufacturing. The company operates two core technology platforms: the IMTB (Immune Tolerance Breaking Technology) platform for antibody discovery and the HiCB (Highly Intensified Continuous Bioprocessing) platform for manufacturing. Its product portfolio centers on Osemitamab (TST001), a Phase III anti-CLDN18.2 antibody for gastric/GEJ cancer and pancreatic cancer, alongside pipeline candidates including TST002 for osteoporosis, TST003 for various solid tumors, TST004 for IgA nephropathy, and multiple ADC and bispecific antibody programs. The HiCB platform is being out-licensed to CDMO partners to enable efficient biologics manufacturing globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Osemitamab (TST001) A high-affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced ADCC activity generated via the IMTB platform, currently in Phase III development for gastric/gastroesophageal junction (G/GEJ) cancer and pancreatic cancer with FDA Orphan Drug Designations in both indications.
• Blosozumab (TST002) A humanized anti-sclerostin monoclonal antibody licensed from Eli Lilly for Greater China, currently in Phase II clinical development for osteoporosis with Transcenta responsible for global commercial manufacturing.
• TST003 A first-in-class high-affinity humanized monoclonal antibody targeting Gremlin-1, currently in Phase I clinical development for solid tumors including colorectal, prostate, gastric, lung, esophageal, pancreatic and breast cancers.
• TST004 A humanized anti-MASP-2 antibody for IgA nephropathy and thrombotic microangiopathy (TMA), co-developed with Alebund Pharmaceuticals for Greater China.
• TST005 A bifunctional fusion protein combining a PD-L1 monoclonal antibody with a TGF-β trap for treating solid tumors, currently in Phase I clinical development.
• TST105 A novel FGFR2b-targeting antibody-drug conjugate site-specifically conjugated with a topoisomerase I inhibitor payload, demonstrating enhanced anti-tumor activity in preclinical gastric and colorectal tumor models.
• TST013 A LIV-1 targeting antibody-drug conjugate (ADC) for treating solid tumors, in preclinical development.
• TST008 A bispecific antibody targeting BAFF/MASP-2 for IgA nephropathy.
• MSB2311 A pH-dependent humanized PD-L1 antibody with a unique intra-tumor recycling property, being developed for TMB-H solid tumors.
• MSB0254 A humanized VEGFR-2 monoclonal antibody inhibiting angiogenesis for treating advanced solid tumors.
• TST801 A bispecific protein targeting BAFF/APRIL for autoimmune diseases.
• TST808 A half-life extended bispecific antibody targeting APRIL for IgA nephropathy.
• Ozekibart (INBRX-109) A DR5 agonist antibody licensed from Inhibrx for Greater China, being developed for chondrosarcoma (BLA submitted to FDA in April 2026) and colorectal cancer.
• HiCB Platform (Continuous Bioprocessing) Proprietary Highly Intensified Continuous Bioprocessing platform integrating continuous perfusion upstream with hybrid continuous downstream purification, offering 10-15x productivity uplift and 50%+ cost of goods reduction versus fed-batch; licensed non-exclusively to global CDMOs and pharma manufacturers.
• Biologics CDMO Services Contract development and manufacturing services leveraging the T-BLOC modular GMP facility (up to 1,500 kg/year protein capacity, 100% batch success rate across 50+ GMP batches) and HiCB continuous bioprocessing platform; spans toxicology batches through Phase I/II/III clinical supply to commercial production for biotech and pharma clients.

Quantifiable outcome

• HiCB platform achieves 10-15 fold productivity increase compared to conventional fed-batch processes
• +8 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• EirGenix Inc. (台康生技)coreTechnology or Integration · 29 December 2025Transcenta entered a strategic collaboration and non-exclusive licensing agreement with EirGenix, Taiwan's largest biopharmaceutical CDMO, granting access to the HiCB (Highly Intensified Continuous Bioprocessing) platform including continuous perfusion upstream and integrated hybrid continuous downstream purification technologies. EirGenix will apply the HiCB platform to serve its CDMO clients pursuing intensified and continuous manufacturing solutions. Transcenta receives substantial upfront payments, milestone payments, and future royalties tied to commercial use of the licensed technologies. This was Transcenta's first HiCB out-licensing deal, with Transcenta receiving a RMB 7 million milestone payment in May 2026.
• Bristol-Myers Squibb (百时美施贵宝)coreStrategic or Co-development PartnerGlobal clinical trial collaboration with Bristol-Myers Squibb to evaluate Osemitamab (TST001) in combination with nivolumab (Opdivo) for first-line treatment of gastric/gastroesophageal junction (G/GEJ) cancer. The collaboration leverages BMS's global clinical development network and nivolumab supply for the TranStar102 study.
• 礼邦医药 (Alebund Pharmaceuticals)coreStrategic or Co-development PartnerJoint venture with Alebund Pharmaceuticals for the development and commercialization of TST004 in Greater China. TST004 is an anti-MASP2 antibody for the treatment of complement-mediated kidney diseases including IgA nephropathy (IgAN) and thrombotic microangiopathy (HSCT-TMA). Transcenta maintains deep strategic involvement in this co-development.
• 默克 (Merck KGaA)coreTechnology or IntegrationCollaboration with Merck KGaA to maximize expertise in continuous bioprocessing, jointly developing automated continuous downstream production facilities and other key technologies. This partnership co-developed the automated continuous downstream component of the HiCB platform.
• 礼来制药 (Eli Lilly)coreOEM/ Whitelabel/ Licensing PartnerLicensed Greater China rights to Blosozumab (TST002) from Eli Lilly for osteoporosis treatment, with priority negotiation rights for global commercialization rights. Transcenta is responsible for global commercial manufacturing of TST002. Lilly had previously completed Phase II trials in the US and Japan showing significant dose-dependent BMD increases.
• 东富龙 (Tofflon)minorChannel Partner/ Reseller/ DistributorStrategic cooperation agreement with Tofflon for market development and sales of cell culture media, leveraging Tofflon's distribution network in the Chinese biopharmaceutical market.
• InhibrxcoreStrategic or Co-development PartnerThrough a 2017 license agreement via Transcenta's subsidiary Hangzhou Just Biotherapeutic (HJB), Transcenta holds exclusive development and commercialization rights in mainland China, Hong Kong, Macau, and Taiwan for ozekibart (INBRX-109), a DR5 agonist antibody. Inhibrx has reported positive Phase II data in chondrosarcoma and colorectal cancer, and submitted a BLA to FDA for conventional chondrosarcoma in April 2026.
• Harvard Medical School / Dana-Farber Cancer InstituteminorStrategic or Co-development PartnerMultiple research collaborations with leading global academic institutions including Dana-Farber Cancer Institute (Harvard Medical School), Peking University Cancer Hospital, Shanghai Pulmonary Hospital, Zhongshan Hospital, and Shanghai Jiao Tong University. Research covers Osemitamab (TST001), TST003, and TST005 programs.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BeiGene (BeOne Medicines): Global oncology biopharmaceutical company founded in China, with approved biologics (Brukinsa, Tislelizumab). Comparable as a China-rooted developer of innovative antibody therapeutics with global clinical and commercial presence.
• Sino Biopharmaceutical: Large China-based pharmaceutical conglomerate with a significant biologics/innovative drug division. Comparable in biologics R&D presence and oncology focus, though at much greater scale and breadth.
• Pharmaron: China-rooted global CRO/CDMO with biologics manufacturing capabilities, serving pharma and biotech clients. Comparable to Transcenta's CDMO/contract services business, though much larger and more diversified across modalities.

Direct peers

• Akeso, Inc. China-based biopharmaceutical company focused on innovative antibody therapeutics, with a strong bispecific antibody pipeline (e.g., ivonescimab). Comparable to Transcenta in oncology biologics development using proprietary antibody platforms.
• GenScript Biotech: Hong Kong-listed biotechnology group with a biologics CDMO arm (GenScript ProBio) covering discovery through GMP manufacturing. Comparable to Transcenta in integrated biologics services and biopharma development.
• Innovent Biologics: China-based biopharmaceutical company developing innovative antibody therapeutics, including oncology mAbs (e.g., PD-1, bispecifics). Comparable to Transcenta as a Chinese-origin innovative antibody developer with both in-house pipeline and biologics manufacturing.
• WuXi Biologics: Hong Kong-listed global leader in biologics CDMO with integrated discovery, development, and manufacturing services. Direct competitor to Transcenta's CDMO and HiCB-licensed bioprocessing services, with much larger scale and broader client base.
• Shanghai Henlius Biotech: China-based biopharmaceutical company combining biosimilars and innovative biologics with integrated manufacturing. Comparable as a Chinese biologics developer/CDMO with oncology pipeline focus.
• Junshi Biosciences: China-based biopharmaceutical company developing innovative antibody therapeutics, including an approved PD-1 (toripalimab) and bispecifics. Comparable as a Chinese antibody developer with global clinical ambitions.

Emerging players

• EirGenix: Taiwan's largest biopharmaceutical CDMO and a Transcenta HiCB platform licensee. Comparable as an Asia-based biologics CDMO directly licensing the HiCB continuous bioprocessing platform for intensified manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Transcenta/featured
• LinkedInlinkedin.com/company/transcenta

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transcenta